Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Botulinum Neurotoxin Subtype A4 Originating from Nontoxigenic Clostridium botulinum.

Literature DB >> 25239910

Botulinum Neurotoxin Subtype A4 Originating from Nontoxigenic Clostridium botulinum.

Donald W Schaffner¹, Harold L Drake².

Abstract

Entities: Species

Mesh：

Substances：

Year: 2014 PMID： 25239910 PMCID： PMC4249198 DOI： 10.1128/AEM.03001-14

Source DB: PubMed Journal: Appl Environ Microbiol ISSN： 0099-2240 Impact factor: 4.792

× No keyword cloud information.

11 in total

1. Genetic diversity among Botulinum Neurotoxin-producing clostridial strains.

Authors: K K Hill; T J Smith; C H Helma; L O Ticknor; B T Foley; R T Svensson; J L Brown; E A Johnson; L A Smith; R T Okinaka; P J Jackson; J D Marks
Journal: J Bacteriol Date: 2006-11-17 Impact factor: 3.490

2. Sequence variation within botulinum neurotoxin serotypes impacts antibody binding and neutralization.

Authors: T J Smith; J Lou; I N Geren; C M Forsyth; R Tsai; S L Laporte; W H Tepp; M Bradshaw; E A Johnson; L A Smith; J D Marks
Journal: Infect Immun Date: 2005-09 Impact factor: 3.441

3. Production of catalytically inactive BoNT/A1 holoprotein and comparison with BoNT/A1 subunit vaccines against toxin subtypes A1, A2, and A3.

Authors: Robert P Webb; Theresa J Smith; Patrick Wright; Jennifer Brown; Leonard A Smith
Journal: Vaccine Date: 2009-05-28 Impact factor: 3.641

4. Exchange of the H(CC) domain mediating double receptor recognition improves the pharmacodynamic properties of botulinum neurotoxin.

Authors: Andreas Rummel; Stefan Mahrhold; Hans Bigalke; Thomas Binz
Journal: FEBS J Date: 2011-06-22 Impact factor: 5.542

5. Botulinum neurotoxin is shielded by NTNHA in an interlocked complex.

Authors: Shenyan Gu; Sophie Rumpel; Jie Zhou; Jasmin Strotmeier; Hans Bigalke; Kay Perry; Charles B Shoemaker; Andreas Rummel; Rongsheng Jin
Journal: Science Date: 2012-02-24 Impact factor: 47.728

6. Novel therapeutics based on recombinant botulinum neurotoxins to normalize the release of transmitters and pain mediators.

Authors: J Oliver Dolly; Jiafu Wang; Tomas H Zurawski; Jianghui Meng
Journal: FEBS J Date: 2011-07-05 Impact factor: 5.542

7. Holotoxin Activity of Botulinum Neurotoxin Subtype A4 Originating from a Nontoxigenic Clostridium botulinum Expression System.

Authors: Marite Bradshaw; William H Tepp; Regina C M Whitemarsh; Sabine Pellett; Eric A Johnson
Journal: Appl Environ Microbiol Date: 2014-09-19 Impact factor: 4.792

Botulinum Neurotoxin Subtype A4 Originating from Nontoxigenic Clostridium botulinum.

1. Genetic diversity among Botulinum Neurotoxin-producing clostridial strains.

2. Sequence variation within botulinum neurotoxin serotypes impacts antibody binding and neutralization.

3. Production of catalytically inactive BoNT/A1 holoprotein and comparison with BoNT/A1 subunit vaccines against toxin subtypes A1, A2, and A3.

4. Exchange of the H(CC) domain mediating double receptor recognition improves the pharmacodynamic properties of botulinum neurotoxin.

5. Botulinum neurotoxin is shielded by NTNHA in an interlocked complex.

6. Novel therapeutics based on recombinant botulinum neurotoxins to normalize the release of transmitters and pain mediators.

7. Holotoxin Activity of Botulinum Neurotoxin Subtype A4 Originating from a Nontoxigenic Clostridium botulinum Expression System.

8. Molecular characterization of a novel botulinum neurotoxin type H gene.

9. A novel strain of Clostridium botulinum that produces type B and type H botulinum toxins.

10. Recombinant derivatives of botulinum neurotoxin A engineered for trafficking studies and neuronal delivery.

1. PilZ Domain Proteins of the Plant Pathogen Xanthomonas oryzae pv. oryzae Function Differentially in Virulence.

2. Dual-Use Research of Concern (DURC) Review at American Society for Microbiology Journals.